Addressing Provider Hesitation Around Medications for Opioid Use Disorder

A clinician can believe that opioid use disorder deserves treatment and still feel uncertain about medication. Concerns may involve diversion, unfamiliar prescribing requirements, limited follow-up capacity, or a treatment culture that equates recovery with taking no medication. Those concerns need different responses; treating all hesitation as stigma can miss the practical problem.

Addressing provider hesitation around medications for opioid use disorder (MOUD) starts with identifying the barrier, reviewing the evidence, and arranging competent care without unnecessary delay. A therapist does not need to become a prescriber, and a prescriber does not need to manage every complexity alone. Each can help make the next step specific and accessible.

This article focuses on provider decisions and referral workflows rather than medication selection. It is professional education, not a prescribing protocol. Initiation, monitoring, and treatment changes require individualized assessment by a qualified clinician.

Separate the medication evidence from the access problem

MOUD includes buprenorphine, methadone, and naltrexone. The National Institute on Drug Abuse's review of MOUD describes evidence that these treatments reduce opioid use. Research also links treatment with buprenorphine or methadone to lower overdose and death risk compared with no treatment. These findings support offering evidence-based options, not promising a particular outcome.

The medications are not interchangeable. Buprenorphine and methadone activate opioid receptors to different degrees and can reduce withdrawal and cravings. Naltrexone blocks opioid receptors; starting it requires a medically assessed opioid-free interval to avoid precipitated withdrawal. Its initiation barriers and evidence should not be collapsed into a single claim that every medication has identical effects on mortality.

For an accessible comparison to share with patients or families, use Waterview's guide to medications for opioid use disorder. The provider task here is different: identify what is preventing an informed offer of treatment and assign responsibility for resolving that obstacle.

Name the hesitation before choosing a response

A useful team conversation asks, “What specifically would need to change for this person to reach appropriate medication care?” The answer often falls into one of four areas:

• Clinical uncertainty: questions about assessment, initiation, interactions, monitoring, or a previous adverse experience call for training or specialist consultation.

• Operational limits: unavailable appointments, pharmacy access, coverage, transportation, and unclear staff responsibilities require an access plan.

• Beliefs about recovery: assuming that prescribed medication invalidates recovery calls for a review of evidence and language.

• Complexity beyond the current setting: medical instability, psychiatric needs, or treatment complications may require additional services or a different level of care.

This distinction reduces blame while keeping the patient at the center. “Our practice cannot safely provide this service today” can be an honest limitation. It should lead to a coordinated alternative, not a conclusion that medication is inappropriate for everyone with similar needs.

Ask the patient about prior treatment, goals, concerns, and practical barriers. Apparent reluctance may reflect an experience of withdrawal, difficulty filling a prescription, or uncertainty about privacy rather than rejection of treatment itself.

Respond to diversion concerns with assessment and proportionate safeguards

Buprenorphine can be diverted or misused, and safety concerns should be taken seriously. SAMHSA's buprenorphine guidance describes its benefits, potential adverse effects, and the importance of safe storage and avoiding dangerous interactions. Medication treatment is not risk-free.

At the same time, NIDA notes that much nonprescribed buprenorphine use is intended to manage withdrawal rather than produce a high. That finding does not establish anyone's motive or make diversion safe. It does caution against assuming that every access problem or unexpected finding reflects an intent to misuse medication.

A qualified treating clinician can review the concern, clarify medication access and use, and determine appropriate follow-up or monitoring. Prescription monitoring and toxicology, when used, should answer a clinical question and be interpreted in context. Uncertainty may warrant consultation; it is not resolved by labeling a person “unreliable.”

Policies should leave room for individualized decisions rather than automatic exclusion. A suspected problem may require a revised plan or another setting, while the risks of interrupted treatment still need attention. This article does not provide testing schedules, dose adjustments, or instructions for managing diversion.

Distinguish physical dependence from opioid use disorder

The phrase “replacing one addiction with another” conflates prescribed treatment with compulsive opioid use that causes harm. Physical dependence means the body has adapted and withdrawal may occur if medication is stopped. Dependence alone does not establish opioid use disorder or mean that treatment has failed.

Buprenorphine and methadone can produce physical dependence while serving a therapeutic role. Evaluation should consider safety, opioid use, symptoms, functioning, patient goals, and adverse effects. Medication use by itself is not a reason to discount progress in work, relationships, or daily routines.

A more useful conversation is, “What is helping, what remains difficult, and what needs reassessment?” Treatment duration is individualized. SAMHSA notes that buprenorphine treatment can be indefinite for some people. An arbitrary medication-free deadline is not a substitute for a shared clinical decision.

Update prescribing knowledge without mistaking permission for competence

SAMHSA's MAT Act guidance on waiver elimination confirms that the federal DATA waiver is no longer required to prescribe buprenorphine for opioid use disorder. Practitioners need a current DEA registration with Schedule III authority and must be permitted to prescribe under applicable state law.

Separate DEA registration-related training requirements still apply where relevant. Waiver elimination does not erase state requirements, professional scope, or the need for clinical competence. Practices should check current requirements rather than rely on an old waiver checklist or assume that every clinician may prescribe.

The change also does not turn an outpatient office into a methadone program. SAMHSA's methadone guidance describes access through certified opioid treatment programs for opioid use disorder. Similarly, its naltrexone guidance explains distinct safety and initiation considerations. These are separate pathways to confirm with the receiving service.

For prescribers building skills, training and mentoring can address clinical uncertainties before they become repeated delays. For nonprescribing professionals, competence includes recognizing the limits of one's role and connecting the patient with someone who can evaluate medication options.

Build a referral pathway that does not create another barrier

A referral is more concrete when the receiving service's role is confirmed. Before describing a plan as arranged, clarify the following with the patient's involvement and appropriate permission:

• Clinical ownership: identify who will evaluate medication needs and who remains responsible for existing treatment until the transition is complete.

• Access: confirm the next contact, how scheduling works, and whether pharmacy, payment, transportation, or clinic hours could interrupt care.

• Communication: establish what information the receiving clinician needs and how it will be shared through appropriate clinical channels.

• Follow-through: identify who will check whether the connection occurred and what to do if the appointment cannot be obtained.

Information sharing must respect HIPAA and applicable substance use record protections, including 42 CFR Part 2. A warm handoff does not justify bypassing consent or sending sensitive treatment information through ordinary email or a public contact form.

Continue to distinguish medication access from access to counseling. SAMHSA's MAT Act guidance states that inability to obtain counseling, or declining it, should not prevent buprenorphine prescribing. Offer behavioral care and practical support without making participation an unnecessary prerequisite to medication evaluation.

Include overdose-prevention planning with the treating clinician, including discussion of overdose-reversal medication and emergency response. Routine referral coordination is not emergency care. If an overdose is suspected, call 911 and use available overdose-reversal medication according to its instructions.

Match additional behavioral support to assessed needs

Some people can receive medication care with standard outpatient follow-up. Others may benefit from more frequent behavioral health contact, skills practice, psychiatric support, or help navigating everyday barriers. The need for MOUD does not automatically establish a need for intensive outpatient treatment.

When mental health concerns occur alongside opioid use, care for co-occurring conditions can bring those needs into the same planning conversation. A behavioral program should complement appropriate medication care, not assume responsibility for an outside prescriber's decisions without an agreed transition.

Waterview Behavioral Health provides adult outpatient behavioral health services in Wallingford, Connecticut. Its published services include group and individual therapy, psychiatric care, and medication management within its outpatient care model. Providers can ask how those services might fit alongside an established prescriber or opioid treatment program.

Do not assume that Waterview dispenses methadone, provides medical withdrawal management, or offers every medication or formulation discussed here. Confirm current capabilities and clinical fit directly. An intensive outpatient program may be considered when added structure is appropriate, while hospital care, withdrawal management, residential treatment, or other outpatient services may better match different needs.

Turn uncertainty into a specific next step

Progress may begin with a consultation rather than a new prescription: identify the concern, ask a qualified colleague for help, confirm a receiving service, or repair a gap in follow-up. The goal is not indiscriminate prescribing. It is an individualized decision in which practical limits and outdated assumptions do not silently determine access.

For a professional conversation about Waterview's outpatient services, assessment, or coordination with an existing care team, call (860) 421-6829 or contact Waterview about referral coordination. Preserve the referring clinician's role and use approved clinical channels for any necessary records. Assessment does not guarantee admission or a particular outcome.

Frequently asked questions

What if a patient declines medication after an informed discussion?

Respect the person's decision, explore concerns without coercion, and keep appropriate care and safety planning available. A qualified clinician can revisit options as circumstances change. Declining medication should not be confused with declining every form of support.

What if there was a previous difficult medication start?

Invite the treating clinician to review what happened rather than assuming all MOUD will have the same result. Prior withdrawal, side effects, access problems, and other medical factors may change the assessment. This requires individualized consultation, not a generic restart schedule.

How should a team respond to a missed appointment?

Use the agreed follow-up process to understand the barrier and reconnect the person with the responsible clinician. A missed visit alone does not explain current medication use, safety, or motivation. Nonprescribing staff should not make medication changes.

Can a therapist support MOUD access without prescribing?

Yes. Therapists can discuss concerns, support informed questions, identify practical obstacles, and coordinate with a qualified prescriber when authorized. They should stay within their scope rather than recommend a medication, dose, or initiation plan.